SCHEMBL10011367

SCHEMBL10011367

OCCNCc1cccc(OCc2ccccc2)c1

nearest known ligand 0.78

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
BCHE P06276 9/20 0.76
CYP4F2 P78329 1/20 0.65
CYP4A11 Q02928 1/20 0.65
MAPK1 P28482 1/20 0.63
MEN1 O00255 2/20 0.59
ALDH1A1 P00352 2/20 0.59
KMT2A Q03164 2/20 0.59
L3MBTL1 Q9Y468 2/20 0.59
KDM4E B2RXH2 1/20 0.59
GAA P10253 1/20 0.59
MAPT P10636 1/20 0.59
THRB P10828 1/20 0.59
PKM P14618 1/20 0.59
RAB9A P51151 1/20 0.59
BLM P54132 1/20 0.59
TDP1 Q9NUW8 1/20 0.58
SPHK2 Q9NRA0 1/20 0.58
SPHK1 Q9NYA1 1/20 0.58

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30821452 1.00 BCHE (0.76) BCHECYP4F2CYP4A11MAPK1MEN1
SCHEMBL21634367 0.97 BCHE (0.72) BCHECYP4F2CYP4A11MAPK1MEN1
SCHEMBL30821677 0.97 BCHE (0.72) BCHECYP4F2CYP4A11MAPK1MEN1
SCHEMBL23120424 0.91 BCHE (0.77) BCHECYP4F2CYP4A11MAPK1MEN1
SCHEMBL14704473 0.89 BCHE (0.60) BCHECYP4F2CYP4A11RAB9ASPHK2
SCHEMBL21634323 0.89 MEN1 (0.65) BCHEMAPK1MEN1KMT2A
SCHEMBL21634318 0.89 SMN1; SMN2 (0.67) BCHEMEN1ALDH1A1KMT2AL3MBTL1
SCHEMBL30821659 0.89 SMN1; SMN2 (0.67) BCHEMEN1ALDH1A1KMT2AL3MBTL1
SCHEMBL28908460 0.89 BCHE (0.68) BCHECYP4F2CYP4A11
SCHEMBL21634358 0.86 SMN1; SMN2 (0.64) BCHEMEN1ALDH1A1KMT2AL3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210163399-A1 NOVEL P62 LIGAND COMPOUND, AND COMPOSITION FOR PREVENTING, AMELIORATING OR TREATING PROTEINOPATHIES COMPRING THE SAME PROTECH CO., LTD. (KR) 2021-06-03 US claimed
EP-3828163-A1 NOVEL P62 LIGAND COMPOUND, AND COMPOSITION FOR PREVENTING, ALLEVIATING, OR TREATING PROTEINOPATHIES COMPRISING SAME Protech Co., Ltd. (KR) 2021-06-02 EP claimed
WO-2020022784-A1 NOVEL P62 LIGAND COMPOUND, AND COMPOSITION FOR PREVENTING, ALLEVIATING, OR TREATING PROTEINOPATHIES COMPRISING SAME 주식회사 프로텍바이오 2020-01-30 WO claimed
EP-3828163-B1 NOVEL P62 LIGAND COMPOUND, AND COMPOSITION FOR PREVENTING, ALLEVIATING, OR TREATING PROTEINOPATHIES COMPRISING SAME AUTOTAC INC (KR) 2026-05-20 EP disclosed
US-12427346-B2 P62 ligand compound, and composition for preventing, ameliorating or treating proteinopathies comprising the same AUTOTAC INC. (KR) 2025-09-30 US disclosed
CN-112424160-B Novel P62 ligand compound and composition for preventing, improving or treating protein conformational diseases comprising the same 奧土择破利悟株式会社 2024-03-08 CN disclosed
US-11802135-B2 Lysophosphatidic acid derivative MITSUBISHI TANABE PHARMA CORPORATION (JP) 2023-10-31 US disclosed
US-11802135-B2 Lysophosphatidic acid derivative MITSUBISHI TANABE PHARMA CORPORATION (JP) 2023-10-31 US disclosed
US-11802135-B2 Lysophosphatidic acid derivative MITSUBISHI TANABE PHARMA CORPORATION (JP) 2023-10-31 US disclosed
US-20230146210-A1 NOVEL LYSOPHOSPHATIDIC ACID DERIVATIVE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2023-05-11 US disclosed
US-20230146210-A1 NOVEL LYSOPHOSPHATIDIC ACID DERIVATIVE MITSUBISHI TANABE PHARMA CORPORATION (JP) 2023-05-11 US disclosed
US-9977150-B2 Second-order nonlinear optical compound and nonlinear optical element comprising the same NATIONAL INSTITUTE OF INFORMATION AND COMMUNICATIONS TECHNOLOGY (JP) 2018-05-22 US disclosed
CN-104610774-B Second nonlinear optic compound and the nonlinear optical element containing it 独立行政法人情报通信研究机构 2017-07-18 CN disclosed
US-9488755-B2 Second-order nonlinear optical compound and nonlinear optical element comprising the same NATIONAL INSTITUTE OF INFORMATION AND COMMUNICATIONS TECHNOLOGY (JP) 2016-11-08 US disclosed
US-20160318889-A1 SECOND-ORDER NONLINEAR OPTICAL COMPOUND AND NONLINEAR OPTICAL ELEMENT COMPRISING THE SAME NAT INST INF & COMM TECH (JP) 2016-11-03 US disclosed
CN-102482504-B Second-order nonlinear optical compound and nonlinear optical element containing the same NATIONAL INSTITUTE OF INFORMATION AND COMMUNICATIONS TECHNOLOGY (JP) 2016-01-20 CN disclosed
CN-104610774-A SECOND-ORDER NONLINEAR OPTICAL COMPOUND AND NONLINEAR OPTICAL ELEMENT COMPRISING THE SAME NAT INST INF & COMM TECH 2015-05-13 CN disclosed
US-20150048284-A1 SECOND-ORDER NONLINEAR OPTICAL COMPOUND AND NONLINEAR OPTICAL ELEMENT COMPRISING THE SAME NAT INST INF & COMM TECH (JP) 2015-02-19 US disclosed
US-8846955-B2 Second-order nonlinear optical compound and nonlinear optical element comprising the same NATIONAL INSTITUTE OF INFORMATION AND COMMUNICATIONS TECHNOLOGY (JP) 2014-09-30 US disclosed
US-20120172599-A1 SECOND-ORDER NONLINEAR OPTICAL COMPOUND AND NONLINEAR OPTICAL ELEMENT COMPRISING THE SAME SUMITOMO ELECTRIC INDUSTRIES, LTD. (JP) 2012-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11802135-B2 Lysophosphatidic acid derivative LPAR4, LPAR2, LPAR1 BCHE 4294/4885CYP4F2 3817/4885CYP4A11 917/4885
US-20160318889-A1 SECOND-ORDER NONLINEAR OPTICAL COMPOUND AND NONLINEAR OPTICAL ELEMENT COMPRISING THE SAME OGFOD1, OCIAD2, OCIAD1 BCHE 1673/4885CYP4F2 744/4885CYP4A11 1734/4885
US-20210163399-A1 NOVEL P62 LIGAND COMPOUND, AND COMPOSITION FOR PREVENTING, AMELIORATING OR TREATING PROTEINOPATHIES COMPRING THE SAME SQSTM1, ATG7, BECN1 BCHE 3322/4885CYP4F2 4355/4885CYP4A11 3690/4885
US-12427346-B2 P62 ligand compound, and composition for preventing, ameliorating or treating proteinopathies comprising the same SQSTM1, ATG7, BECN1 BCHE 3594/4885CYP4F2 4416/4885CYP4A11 3826/4885
US-20150048284-A1 SECOND-ORDER NONLINEAR OPTICAL COMPOUND AND NONLINEAR OPTICAL ELEMENT COMPRISING THE SAME OGFOD1, OCIAD2, OCIAD1 BCHE 1673/4885CYP4F2 744/4885CYP4A11 1734/4885
US-20230146210-A1 NOVEL LYSOPHOSPHATIDIC ACID DERIVATIVE LPAR4, LPAR2, LPAR1 BCHE 4355/4885CYP4F2 3824/4885CYP4A11 1080/4885
US-20120172599-A1 SECOND-ORDER NONLINEAR OPTICAL COMPOUND AND NONLINEAR OPTICAL ELEMENT COMPRISING THE SAME OGFOD1, OCIAD2, OCIAD1 BCHE 1673/4885CYP4F2 744/4885CYP4A11 1734/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.